Institut de Génétique et de Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique/Institut National de la Santé et de la Recherche Médicale/Université de Strasbourg, 67404 Illkirch, France.
J Neurosci. 2010 Dec 8;30(49):16459-68. doi: 10.1523/JNEUROSCI.3748-10.2010.
δ-Opioid receptors are G-protein-coupled receptors that regulate nociceptive and emotional responses. It has been well established that distinct agonists acting at the same G-protein-coupled receptor can engage different signaling or regulatory responses. This concept, known as biased agonism, has important biological and therapeutic implications. Ligand-biased responses are well described in cellular models, however, demonstrating the physiological relevance of biased agonism in vivo remains a major challenge. The aim of this study was to investigate the long-term consequences of ligand-biased trafficking of the δ-opioid receptor, at both the cellular and behavioral level. We used δ agonists with similar binding and analgesic properties, but high [SNC80 ((+)-4-[(αR)-α-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide)]- or low [ARM390 (N,N-diethyl-4-(phenyl-piperidin-4-ylidenemethyl)-benzamide)]-internalization potencies. As we found previously, a single SNC80-but not ARM390-administration triggered acute desensitization of the analgesic response in mice. However, daily injections of either compound over 5 d produced full analgesic tolerance. SNC80-tolerant animals showed widespread receptor downregulation, and tolerance to analgesic, locomotor and anxiolytic effects of the agonist. Hence, internalization-dependent tolerance developed, as a result of generalized receptor degradation. In contrast, ARM390-tolerant mice showed intact receptor expression, but δ-opioid receptor coupling to Ca²+ channels was abolished in dorsal root ganglia. Concomitantly, tolerance developed for agonist-induced analgesia, but not locomotor or anxiolytic responses. Therefore, internalization-independent tolerance was produced by anatomically restricted adaptations leading to pain-specific tolerance. Hence, ligand-directed receptor trafficking of the δ-opioid receptor engages distinct adaptive responses, and this study reveals a novel aspect of biased agonism in vivo.
δ-阿片受体是 G 蛋白偶联受体,可调节伤害感受和情绪反应。已经证实,作用于同一 G 蛋白偶联受体的不同激动剂可以引起不同的信号转导或调节反应。这种概念称为偏激动剂,具有重要的生物学和治疗意义。配体偏向反应在细胞模型中得到了很好的描述,然而,证明体内偏激动剂的生理相关性仍然是一个主要挑战。本研究旨在研究 δ-阿片受体配体偏向转运的长期后果,包括细胞和行为水平。我们使用具有相似结合和镇痛特性但内化能力不同的 δ 激动剂,高内化能力的[SNC80(+)-4-[(αR)-α-[(2S,5R)-4-烯丙基-2,5-二甲基-1-哌嗪基]-3-甲氧基苄基]-N,N-二乙基苯甲酰胺]和低内化能力的[ARM390 (N,N-二乙基-4-(苯基-哌啶-4-亚基甲基)-苯甲酰胺)]。正如我们之前发现的,单次 SNC80 给药而不是 ARM390 给药会引发小鼠镇痛反应的急性脱敏。然而,连续 5 天每天注射这两种化合物都会产生完全的镇痛耐受。SNC80 耐受的动物表现出广泛的受体下调,以及对激动剂的镇痛、运动和抗焦虑作用的耐受。因此,由于普遍的受体降解,产生了依赖内化的耐受。相比之下,ARM390 耐受的小鼠表现出完整的受体表达,但 δ-阿片受体与钙通道的偶联在背根神经节中被消除。同时,对于激动剂诱导的镇痛作用产生了耐受,但对运动或抗焦虑反应没有耐受。因此,通过导致疼痛特异性耐受的解剖受限适应产生了不依赖内化的耐受。因此,δ-阿片受体的配体定向受体转运会引发不同的适应性反应,本研究揭示了体内偏激动剂的一个新方面。